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Specific glycosaminoglycans promote unseeded
amyloid formation from b2-microglobulin under
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Dialysis-related amyloidosis (DRA) is a complication of
hemodialysis where b2-microglobulin (b2m) forms plaques
mainly in cartilaginous tissues. The tissue-specific deposition,
along with a known intransigence of pure b2m to form fibrils
in vitro at neutral pH in the absence of preformed fibrillar
seeds, suggests a role for factors within cartilage in
enhancing amyloid formation from this protein. To identify
these factors, we determined the ability of a derivative
lacking the N-terminal six amino acids found in ex vivo b2m
amyloid deposits to form amyloid fibrils at pH 7.4 in the
absence of fibrillar seeds. We show that the addition of the
glycosaminoglycans (GAGs) chrondroitin-4 or 6-sulfate to
fibril growth assays results in the spontaneous generation of
amyloid-like fibrils. By contrast, no fibrils are observed over
the same time course in the presence of hyaluronic acid, a
nonsulfated GAG that is abundant in cartilaginous joints.
Based on the observation that hyaluronic acid has no effect
on fibril stability, while chrondroitin-6-sulfate decreases the
rate of fibril disassembly, we propose that the latter GAG
enhances amyloid formation by stabilizing the rare fibrils that
form spontaneously. This leads to the accumulation of b2m in
fibrillar deposits. Our data rationalize the joint-specific
deposition of b2m amyloid in DRA, suggesting mechanisms
by which amyloid formation may be promoted.
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b2-microglobulin (b2m) is the nonpolymorphic subunit of
the major histocompatibility complex class I molecule, which
is expressed on the surface of all nucleated cells.1 b2m is
continually shed from cell surface major histocompatibility
complex molecules and is normally removed from the
circulation by the kidney.2 However, in patients with end-
stage renal disease neither the kidney nor hemodialysis
remove b2m efficiently from the circulation, leading to an up
to 60-fold increase in the serum concentration of b2m.
Ultimately, this leads to the deposition of b2m amyloid
fibrils, which occurs predominantly in the cartilaginous
joints.2–5 These b2m amyloid deposits cause progressive bone
and joint destruction, resulting in severe skeletal morbidity
associated with dialysis-related amyloidosis (DRA).
b2m is 99 residue protein that has a seven-stranded all b-
sheet fold typical of the immunoglobulin superfamily.6 In
vitro, wild-type b2m can be readily induced to form amyloid-
like fibrils by partially or more completely denaturing the
protein at acidic pH7–10 and the assembly pathways and
morphologies of the fibrils formed under these conditions
have been studied in detail.11,12 Recent studies have also
demonstrated that a partially unfolded conformation of b2m
populated at pH 7.0 in which a non-native trans isomer of
proline is formed at residue 32 is able to elongate fibril seeds,
suggesting this species may be involved in amyloid formation
in vivo.13 In addition, wild-type b2m extends preformed fibril
seeds at neutral pH in the presence of sodium dodecyl
sulfate,14 mixtures of glycosaminoglycans (GAGs), trifluoro-
ethanol15 or GAGs alone.16 These data indicate that
although b2m can extend preformed fibrillar seeds at neutral
pH, spontaneous (unseeded) fibril formation is highly
inefficient under these conditions. Identifying physiologically
relevant components that promote amyloid deposition at
neutral pH, therefore, remains a key issue.
Previous studies have suggested a role for collagen17 and/
or GAGs18–21 in promoting b2m fibrillogenesis at physiolo-
gical pH, consistent with the observation that b2m amyloid
deposits are first observed in the superficial layer of
cartilage.22 One of the most extensively studied GAGs is
heparin, which has been shown to significantly increase the
rate of fibril formation in vitro of b-synuclein, gelsolin, and
b-amyloid (at physiological pH).23–25 With regard to b2m
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fibrils, heparin has been shown to increase the rate of fibril
elongation at pH 7.0 in the presence of trifluoroethanol and
to decrease the rate of depolymerization of fibrils formed
under acidic conditions when incubated at neutral pH.15,16,26
Whether heparin or other GAGs are also able to promote
fibril deposition in the absence of added seeds, however,
remains unknown.
To investigate the role of GAGs in the initiation of b2m
fibril deposition, we used DN6b2m, a physiologically relevant
truncated form of b2m lacking the N-terminal six amino
acids that constitutes up to 30% of the b2m in fibrils purified
from DRA patients.27 Although retaining a native-like fold,
DN6b2m is destabilized compared with wild-type b2m,
28 has
an increased propensity to extend preformed fibril seeds
compared with its wild-type counterpart at pH 4–8,16,28
and can form fibrils, albeit with extremely low yields, at pH
7.0 in the absence of fibrillar seeds.16 Fibrils formed from
DN6 and wild-type b2m are structurally indistinguishable;
16,28,29
indeed, the N-terminus of b2m is solvent exposed in fibrils
formed from the wild-type protein indicating that this region
is not integral to fibril structure.30–32 These properties make
DN6b2m an ideal model system with which to study the role
of GAGs in fibrillogenesis under physiologically relevant
conditions, within an experimentally tractable timeframe. All
experiments were performed in the absence of seeds, at
physiological temperature, pH, and ionic strength, in the
absence of denaturant, detergents, or organic solvent. We
show that over a 4-week period, DN6b2m remains non-
fibrillar at physiological pH (7.4). However, significant
increases in amyloid content were observed over the same
time period in reactions containing chondroitin-4-sulfate or
chondroitin-6-sulfate, which are found in high concentra-
tions in cartilage.33,34 By contrast, hyaluronic acid, which is
also abundant in cartilaginous joints,35 had no effect.
Together with analysis of the effect of these additives on
the structure of native DN6b2m and the rates of fibril
disassembly at pH 7.4, we propose a mechanism to describe
how specific GAGs promote the onset of fibril deposition
within the cartilaginous joints of hemodialysis patients.
RESULTS
Heparin and chondroitin sulfate induce fibrillogenesis of
DN6b2m at physiological pH
A panel of GAGs was screened for their ability to promote the
fibrillogenesis of DN6b2m in the absence of seeds under
physiological conditions (pH 7.4, 137 mM NaCl, 2.7 mM KCl,
371C). In contrast to previous studies of the effects of GAGs
on fibril elongation,15 no organic solvents or other non-
natural additives were added. The GAGs screened were
chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sul-
fate, heparan sulfate, and hyaluronic acid, all of which are
present in the cartilaginous joints, as well as heparin, an
anticoagulant used during hemodialysis.36 Fibrillogenesis was
monitored using three independent assays: immunoblotting
with the amyloid-specific antibody WO1 that binds to b2m
fibrils formed both in vitro and in vivo16,37(SE Radford, IJ
Morten, and EW Hewitt, unpublished results), binding of the
amyloid-specific dye thioflavin T (thioT),38 and negative-
stain electron microscopy (EM).
A standardized methodology was used in the purification
and preparation of DN6b2m for fibrillation assays to ensure
that all experiments commenced with identical protein
samples (see Materials and Methods).8 In addition, to ensure
that any differences in fibril growth rates observed could be
attributed unequivocally to the GAG added, the screen was
repeated three times and all reactions were set up in duplicate
containing 2 mg/ml DN6b2m from the same preparation with
either 5.0, 0.05, or 0 mg/ml GAGs (see Materials and
Methods). In all screens, none of the samples at time zero
showed a significant increase in thioT fluorescence or
antibody binding compared with DN6b2m alone (Figure 1a
and b). Likewise, no significant change was observed in
reactions containing no additive or up to 5 mg/ml hyaluronic
acid, even after 4 weeks of incubation (Figure 1a and 1b).
Dermatan sulfate and heparan sulfate also had no significant
effect on DN6b2m fibrillogenesis (data not shown). Strik-
ingly, however, in the presence of heparin, chrondroitin-4-
sulfate, or chrondroitin-6-sulfate, a significant increase in
thioT fluorescence was observed over time, culminating in an
eight to 14-fold increase after 4 weeks (Figure 1b). Similarly,
WO1 immunoreactivity was observed in the samples
containing heparin, chrondroitin-4-sulfate, or chrondroitin-
6-sulfate after 4 weeks incubation, but not in their absence
(Figure 1a). These results were consistent in all of the screens,
demonstrating that heparin, chrondroitin-4-sulfate, and
chrondroitin-6-sulfate specifically promote fibril formation
and that the observed effects can be attributed to the addition
of these GAGs rather than differences in the DN6b2m
preparations. No clear concentration dependence was
observed, suggesting that these GAGs are saturating at these
mass ratios, mirroring the situation in vivo where the GAG
concentration in the cartilaginous tissues is likely to exceed
that of b2m.
34 By contrast with these results, no increase in
thioT fluorescence or binding by the amyloid-specific antibody
WO1 was observed for wild-type b2m even after 10 weeks
incubation with 5.0 mg/ml of heparin and no fibrils were
observed by negative-stain EM (data not shown), consistent
with the known intransigence of wild-type b2m to form
amyloid fibrils in the absence of seeds at neutral pH.39,40
To further demonstrate the presence of amyloid fibrils in
the reactions containing chrondroitin-4-sulfate, chrondroi-
tin-6-sulfate, or heparin, samples were also assayed for their
ability to bind the amyloid-specific dye, Congo red (Figure
2a-c). Fibrils formed in the presence of heparin (Figure 2a),
chrondroitin-4-sulfate (Figure 2b), or chrondroitin-6-sulfate
(Figure 2c), all bind Congo red, displaying changes in the
absorbance spectrum of the dye characteristic of binding to
amyloid fibrils.41 The fibrils also show a classical amyloid-
like, long-straight morphology when imaged by EM (Figure
2d–f), confirming the ability of these GAGs to promote the
spontaneous formation of amyloid-like fibrils in the absence
of seeds or other additives.
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The conformation of DN6b2m is unchanged in the
presence of GAGs
To investigate the mechanism by which GAGs promote fibril
formation from b2m in more detail, the effect of heparin and
chrondroitin-6-sulfate (which is 20-fold more abundant than
chrondroitin-4-sulfate in adult joints42) on the structural
properties of DN6b2m was analyzed using far and near UV
circular dichroism (CD) (Figure 3a and b). GAGs were added
to the protein at a w/w ratio comparable with that used in the
assays described above and any effect on the structural
properties of DN6b2m were examined immediately upon
addition of each GAG (see Materials and Methods). The far
and near UV CD spectra of DN6b2m were not altered
substantially by the presence of the GAG, demonstrating that
the structural properties of the protein remain largely
unperturbed in the presence of these additives. The changes
in the far UV CD spectrum below 210 nm may reflect small
changes in aromatic ring chromophores in the presence of
the GAGs. Consistent with this notion, GAGs are known to
bind to regions of the b2m sequence that include aromatic
residues.43 Even after overnight incubation at 371C with
agitation (200 r.p.m.), no further changes were observed in
the far or near UV CD, confirming that DN6b2m remains
natively folded in the presence of the GAGs (data not shown).
The ability of these GAGs to enhance fibrillogenesis of b2m,
therefore, does not appear to result from the direct
perturbation of the native structure of the protein.
Fibril depolymerization in the presence of GAGs
GAGs stabilize amyloid fibrils formed in vitro from a number
of different proteins.44 Previous studies have shown that
heparin stabilizes b2m amyloid fibrils formed at pH 2.5
against depolymerization at neutral pH,16 although chon-
droitin sulfate was reported to have little or no effect.26 To
examine whether the different effects of heparin, chrondroi-
tin-6-sulfate, and hyaluronic acid in fibril formation could
result from differences in fibril stability in the presence of
these additives, fibrils formed by incubating wild-type b2m at
pH 2.5 were diluted to pH 7.4 and the kinetics of
depolymerization were monitored by the fluorescence of
thioT (see Materials and Methods). The results were striking;
revealing that heparin and chrondroitin-6-sulfate signifi-
cantly reduced the rate of fibril depolymerization at pH 7.4
(Figure 4a and b). Indeed, at a protein:GAG (w/w) ratio of
1:1 (equivalent to an added concentration of 20 mg/ml GAG)
the initial rate of fibril depolymerization was reduced by
approximately 65 and 30% in the presence of heparin and
chrondroitin-6-sulfate, respectively (Figure 4d), whereas
hyaluronic acid was completely ineffective (Figure 4c and d).
The data indicate the very different effects of these three
GAGs on fibril stability, with heparin providing the greatest
protection, chrondroitin-6-sulfate being less effective, and
hyaluronic acid completely ineffective in stabilizing the fibrils
formed under the conditions used.
DISCUSSION
Given the apparent inability of b2m to form fibrils when
incubated as pure protein in the absence of seeds at neutral
pH,39,40 one of the major questions in DRA is the mechanism
by which b2m forms fibrils under physiological conditions. In
this study, we have shown that specific GAGs present within
cartilage can promote the formation of amyloid-like fibrils
from DN6b2m at pH 7.4 and 371C in the absence of fibrillar
seeds, detergents, metal ions, or organic solvents,14–16,26,45
suggesting one route by which amyloidosis of this protein
may occur in vivo.
b2m amyloid deposition is tissue specific, with the
cartilaginous joints representing the major site of amyloid
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Figure 1 | The effect of GAGs on the fibrillogenesis of DN6b2m. All reactions were performed in PBS (pH 7.4) with 2.0 mg/ml protein
and either 0.05 or 5.0 mg/ml GAG. Data for hyaluronic acid are shown at 5.0 mg/ml. (a) Binding of the antifibrillar antibody WO137 at 0 and
4 weeks. (b) ThioT fluorescence of equivalent samples at weekly intervals from 0 to 4 weeks. The data are representative of three independent
experiments. C4S, chondroitin-4-sulfate; C6S, chondroitin-6-sulfate; obs, observed.
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deposition. In the sternoclavicular joint, amyloid deposits are
observed within the superficial layer of cartilage,22 suggesting
a key role for cartilage in facilitating b2m fibrillogenesis
in vivo at physiological pH. Our data support this notion, as
both chondroitin-4-sulfate and chondroitin-6-sulfate are
abundant components of cartilage.33,34 Previous studies have
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Figure 2 | Congo red binding and EM images of DN6b2m fibrils formed in the presence of different GAGs. Absorbance spectrum of Congo
red bound to DN6b2m fibrils formed in the presence of (a) heparin, (b) chondroitin-4-sulfate, or (c) chondroitin-6-sulfate. Congo red in the
presence of DN6b2m fibrils (red line); monomeric DN6b2m (black line), and GAG alone (green line). The inset shows the difference spectrum
((Congo redþprotein)(Congo red alone)) for DN6b2m fibrils (red line) and DN6b2m monomer (green line). Negative-stain EM images of
DN6b2m fibrils formed in the presence of (d) heparin, (e) chondroitin-4-sulfate, or (f) chondroitin-6-sulfate. Bar represents 100 nm. au, arbitrary
units; Abs, absorbance.
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Figure 3 | Far and near UV CD spectra of DN6b2m in the presence of different GAGs. (a) Far and (b) near UV CD spectra of DN6b2m
in the presence of heparin (red), chondroitin-6-sulfate (green), hyaluronic acid (blue), or in the absence of GAG (black). In all spectra containing
GAGs, the protein:GAG ratio (w/w) was 0.3:1.0.
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also shown that chondroitin sulfate is found in association
with ex vivo b2m amyloid fibrils,
18 consistent with a role for
these GAGs in amyloid deposition in vivo. That not every
GAG present in cartilaginous joints promoted fibril assembly,
as demonstrated here using hyaluronic acid, further high-
lights the specific ability of chondroitin sulfate to promote
fibril assembly, reinforcing the role of the latter GAG in the
tissue-specific deposition of b2m amyloid. Collagen is
another component of cartilage that may promote fibrillo-
genesis of b2m. Collagen fibrils are often found in association
with ex vivo b2m amyloid deposits and recent studies have
shown that both wild-type b2m and DN6b2m bind to type I
collagen at pH7.4 with a Kd of 4.1 104 and 3.5 105 M,
respectively.46 In addition, type I collagen from skin has been
shown to promote fibrillogenesis of wild-type b2m in vitro at
pH 6.4.17 Although this degree of acidity is only likely to be
found in severely inflamed joints,47 the data nonetheless
suggest a potential role for collagen in promoting amyloid
formation. It has been proposed that collagen forms a
positively charged surface, to which the negatively charged
b2m binds, hence increasing the local concentration of
monomer and, as a consequence, promoting fibril forma-
tion.17 Together with the effects of GAGs presented here, the
data rationalize why cartilaginous joints are the major site for
amyloid deposition in hemodialysis patients and highlight
the importance of multiple factors within the local environ-
ment that may act in concert to stimulate fibril deposition in
DRA and other amyloid disorders.48
Both chondroitin-6-sulfate and heparin carry a high net
negative charge at neutral pH. By contrast, the nonsulfated
GAG, hyaluronic acid, contains only a single negative charge
per disaccharide unit. Perhaps surprisingly, given that the net
charge of DN6b2m at neutral pH is 4.3,46 an increased
negative charge appears to enhance the ability of these GAGs
to stabilize b2m fibrils against depolymerization at pH 7.4.
Indeed, the degree of sulfation correlates with the ability of
these GAGs to stabilize fibrils at this pH, with heparin being
more effective than chondroitin-6-sulfate, while hyaluronic
acid has no effect. The data suggest that the arrangement of
amino-acid side chains in the fibril must either provide a
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Figure 4 | Depolymerization of b2m fibrils at neutral pH in the presence of different GAGs. The kinetics of fibril depolymerization
were monitored using the fluorescence of thioT (see Materials and Methods). Each reaction was monitored either with no additive or in the
presence of 1.0, 5.0, 10.0, or 20.0 mg/ml (a) heparin, (b) chondroitin-6-sulfate, (c) or hyaluronic acid. The maximum protein:GAG ratio (w/w)
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Figure 5 | Schematic diagram showing the role of GAGs on fibril
formation from b2m. Monomeric b2m forms amyloid fibrils by a
nucleation-growth mechanism.13,30 At pH 7.4, in the absence of
stabilizing factors, the fibril yield depends on the probability of
stochastic nucleation and the stability of the fibrils formed. Simply by
stabilizing fibrils, therefore, by the addition of GAGs or other
physiologically relevant factors, fibril yield can be enhanced without
necessarily altering the probability of nucleation events.
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potent binding site for sulfated GAGs or the cross b structure
of amyloid must increase the pI of the protein subunits
substantially relative to the monomeric form. Further
insights into the structure of amyloid fibrils are required to
determine the precise manner by which these GAGs bind and
stabilize these and other44 amyloid fibrils.
Previous results have shown that partial or more
complete unfolding of b2m is required for the formation of
amyloid-like fibrils under acidic conditions in vitro.49–51
Although heparin and chondroitin-6-sulfate both bind to
monomeric b2m,
43 neither GAG substantially perturbs the
native structure of DN6b2m nor do they affect its thermo-
dynamic stability.16 This contrasts with studies of b-amyloid,
serum amyloid A, and amylin, in which these GAGs were
shown to increase b-sheet structure with a concomitant
increase in the rate of fibril formation.23,52,53 As such, our
data do not suggest that heparin and chondroitin-6-sulfate
promote fibril formation by increasing the efficiency of
nucleation, although we cannot exclude the possibility that a
small subpopulation of DN6b2m molecules may have been
converted into a more fibrillogenic form in the presence of
these additives.
Both heparin and chondroitin-6-sulfate inhibit the
depolymerization of b2m fibrils at pH 7.4; the latter is a
novel finding as it contrasts with a previous study, in which
chrondroitin-6-sulfate was reported to have no effect on the
stability of b2m fibrils incubated at pH 7.5.
26 The inhibition
of b2m fibril depolymerization by heparin and chondroitin-
6-sulfate is concentration dependent, suggesting that at low
GAG concentrations fibril assembly would be highly
inefficient, simply because the equilibrium would favor the
monomer or lower order oligomers at low GAG concentra-
tions. As the combined concentration of chondroitin sulfates
in cartilage (27.8 mg/g of tissue)34 is substantially greater
than that used in this study, the data suggest that stabilization
of fibrils by chondroitin-6-sulfate would favor fibril forma-
tion in vivo, rationalizing the deposition of b2m amyloid
deposits in the cartilaginous tissues.
Based on our observations, we propose that heparin and
chondroitin-6-sulfate act by stabilizing rare fibrils that form
stochastically by random nucleation events, hence driving the
equilibrium towards fibril deposition and increasing fibril
deposition with time (Figure 5). Thus stabilizing the fibrillar
form, without a direct effect on nucleation, is sufficient for
these GAGs to promote fibril formation. The enhanced
probability of fibril formation of DN6b2m provides one route
by which fibril deposition of the full-length protein may be
enhanced, as DN6b2m fibrils have the capacity to cross-seed
fibril assembly from wild-type b2m (TR Jahn and SE
Radford, unpublished results). Although more detailed
experiments will be needed to identify the precise kinetic
steps affected by these additives, our results suggest at least
one mechanism by which fibril deposition could be enhanced
in vivo by the specific action of GAGs in stabilizing fibril
formation in an environment pertinent to the cartilaginous
tissues in which these fibrils accumulate.
MATERIALS AND METHODS
Materials
All reagents unless otherwise indicated were purchased from Sigma-
Aldrich (Poole, Dorset, UK).
In vitro fibrillogenesis of DN6b2m under physiological
conditions
DN6b2m was expressed and purified as described previously.
16
Lyophilized DN6b2m was dissolved in phosphate-buffered saline
(PBS) (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM
KH2PO4; pH 7.4), syringe filtered (0.22mm) and diluted to a final
concentration of 4.0 mg/ml with PBS. This solution was then mixed
1:1 v/v with a solution containing the GAG in PBS at a
concentration of either 10.0 or 0.10 mg/ml. The GAGs used were
low-molecular weight heparin (H8537), chondroitin-4-sulfate
(C9819), chondroitin-6-sulfate (C4384), dermatan sulfate (C3788),
heparan sulfate (H9902), or hyaluronic acid (H5388), all of which
were purchased from Sigma-Aldrich. All GAGs were dissolved in
PBS and syringe filtered (0.22 mm); each sample was made in
duplicate at a final volume of 250ml. Controls, containing DN6b2m
alone, were made in PBS without GAG. By performing experiments
in parallel in this manner, any differences in fibril growth rates could
be attributed directly to the presence of the GAG, while ensuring the
reproducibility of the observations made. Wild-type b2m was used
at 4.0 mg/ml with or without the addition of 1:1 v/v 10.0 mg/ml low-
molecular weight heparin. In all instances, the final protein concentra-
tion was 2.0 mg/ml and the GAG concentration was either 5.0 or
0.05 mg/ml. Each tube also contained amphotericin B, sodium azide,
carbenicillin, ethylenediaminetetraacetic acid, 4-(2-aminoethyl) benze-
nesulfonyl fluoride hydrochloride, antipain, and phosphoramidon at
0.25 mg/ml, 0.2% w/v, 100mg/ml, 1, 100, 10, and 1mM, respectively.
Each sample was incubated at 371C with agitation (200 r.p.m.) for 4
weeks. A 25-ml aliquot of each reaction was taken at time zero then each
week for 4 weeks under sterile conditions; each aliquot was mixed with
its duplicate and the pooled samples snap-frozen on dry ice and stored
at201C for later analysis by thioT fluorescence and immunoreactivity
with the anti-amyloid antibody WO1.37
Immunoblotting, Congo red binding and EM
Immunoblotting with the generic anti-amyloid antibody WO137 was
performed as described previously.12 Congo red binding was
performed as described54 using equimolar Congo red:b2m. Negative-
stain EM was performed as described previously.9 The fibrillar content
was assessed by centrifuging 100ml of sample at 13 000 r.p.m. for 10 min
in a microcentrifuge. After centrifugation the supernatant was removed
and the pellet resuspended in 100ml PBS and added to 900ml of 6 M
guanidine hydrochloride (pH 8.0), which was then mixed gently on a
rocking table for 2 h at room temperature. The fibrillar content was
derived from the mean value absorption of the denatured state at
280 nm of three individual samples, using extinction coefficients
determined by the method of Gill and von Hippel.55
ThioT fluorescence
The thioT fluorescence of each sample was followed discontinuously
as described previously.9 The fluorescence intensity shown is the
mean of the pooled duplicate samples.
Fibril depolymerization in the presence of GAG
Amyloid fibrils were formed by incubating wild-type b2 m (1 mg/ml)
at 371C for 7 days in 25 mM sodium phosphate and 25 mM
Kidney International (2007) 72, 174–181 179
AJ Borysik et al.: Glycosaminoglycans in dialysis-related amyloidosis o r i g i n a l a r t i c l e
sodium acetate buffer at pH 2.5, as described previously.8 The
fibrillar suspension was centrifuged at 13 000 r.p.m. for 10 min in a
microcentrifuge, then the supernatant was removed and the pellet
resuspended, with vortexing, in 100 ml of 25 mM sodium phosphate
and 25 mM sodium acetate at pH 2.5. Seeds were created by three
successive rounds of rapid freeze–thawing using a dry-ice bath and
the samples stored at 201C. Fibril depolymerization was
monitored in real time on a PTI Quantamaster C-61 spectro-
fluorimeter in PBS, as described previously.16 First, a 100-ml aliquot
of fibril seeds was thawed on ice. Fibrillar content was assessed by
adding 10 ml of the thawed fibrillar suspension to 990ml 6 M
guanidine hydrochloride pH 8.0, which was then mixed gently on a
rocking table for 2 h at room temperature. The fibrillar content was
derived from the mean value absorption of the denatured state at
280 nm of three individual samples, using extinction coefficients
determined by the method of Gill and von Hippel.55 Next, a 5-ml
aliquot of the thawed fibril seeds was added to a volume of PBS,
containing (10 mM) thioT and various concentrations of GAG,
required to dilute the seeds to a concentration equivalent to 2 mM
monomer, the PBS having been heated to 371C. The sample was
immediately mixed with vortexing and the fluorescence of a 1-ml
aliquot followed for 30 min using excitation and emission
wavelengths of 444 and 480 nm, respectively. Samples were rapidly
mixed with a magnetic stirrer during data acquisition. Duplicate
kinetic fluorescence measurements were carried out at 0, 1.0, 5.0,
10.0, and 20.0 mg/ml heparin, chondroitin-6-sulfate, and hyaluronic
acid. Rates were calculated from the mean least squares fit of a single
exponential decay to each trace using SigmaPlot 2001 (SPSS Inc,
Chicago, IL).
Far and near UV CD
CD experiments were performed on a Jasco J715 CD spectro-
polarimeter. Far and near UV CD spectra were recorded using a
protein concentrations of 0.3 and 0.6 mg/ml, respectively. All
experiments were performed in PBS with 1.0 and 2.0 mg/ml GAG
for far and near UV CD, respectively. All samples were filtered
(0.22mm) before analysis. Spectra were acquired at 371C as
described previously8 with absorbance blanked against a solution
of the GAG alone.
ACKNOWLEDGMENTS
We thank Ron Wetzel (University of Pittsburgh) for the WO1
antibody and the SER group for helpful discussions. This work
was supported by Kidney Research UK (AJB and IJM) and the BBSRC
(SER).
REFERENCES
1. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen
processing. Annu Rev Immunol 1998; 16: 323–358.
2. Floege J, Ehlerding G. Beta-2-microglobulin-associated amyloidosis.
Nephron 1996; 72: 9–26.
3. Gejyo F, Homma N, Suzuki Y et al. Serum levels of beta-2-microglobulin as
a new form of amyloid protein in patients undergoing long-term
hemodialysis. N Engl J Med 1986; 314: 585–586.
4. Floege J, Ketteler M. Beta-2-microglobulin-derived amyloidosis: an
update. Kidney Int 2001; 59(Suppl 78): S164–171.
5. van Ypersele De Strihou C, Jadoul M, Garbar C. Morphogenesis of joint
beta-2-microglobulin amyloid deposits. Nephrol Dial Transplant 2001;
16(Suppl 4): 3–7.
6. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human
histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 1991;
219: 277–319.
7. McParland VJ, Kad NM, Kalverda AP et al. Partially unfolded states of
beta-2-microglobulin and amyloid formation in vitro. Biochemistry 2000;
39: 8735–8746.
8. Kad NM, Thomson NH, Smith DP et al. Beta-2-microglobulin and its
deamidated variant, N17D form amyloid fibrils with a range of
morphologies in vitro. J Mol Biol 2001; 313: 559–571.
9. Smith DP, Jones S, Serpell LC et al. A systematic investigation into the
effect of protein destabilisation on beta-2-microglobulin amyloid
formation. J Mol Biol 2003; 330: 943–954.
10. Naiki H, Hashimoto N, Suzuki S et al. Establishment of a kinetic-model of
dialysis-related amyloid fibril extension in-vitro. Int J Exp Clin Invest 1997;
4: 223–232.
11. Kad NM, Myers SL, Smith DP et al. Hierarchical assembly
of beta-2-microglobulin amyloid in vitro revealed by atomic force
microscopy. J Mol Biol 2003; 330: 785–797.
12. Gosal WS, Morten IJ, Hewitt EW et al. Competing pathways determine
fibril morphology in the self-assembly of beta-2-microglobulin into
amyloid. J Mol Biol 2005; 351: 850–864.
13. Jahn TR, Parker MJ, Homans SW, Radford SE. Amyloid formation under
physiological conditions proceeds via a native-like folding intermediate.
Nat Struct Mol Biol 2006; 13: 195–201.
14. Yamamoto S, Hasegawa K, Yamaguchi I et al. Low concentrations
of sodium dodecyl sulfate induce the extension of
beta-2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry
2004; 43: 11075–11082.
15. Yamamoto S, Yamaguchi I, Hasegawa K et al. Glycosaminoglycans
enhance the trifluoroethanol-induced extension of
beta-2-microglobulin-related amyloid fibrils at a neutral pH. J Am Soc
Nephrol 2004; 15: 126–133.
16. Myers SL, Jones S, Jahn TR et al. A systematic study of the effect of
physiological factors on beta-2-microglobulin amyloid formation at
neutral pH. Biochemistry 2006; 45: 2311–2321.
17. Relini A, Canale C, De Stefano S et al. Collagen plays an active role in the
aggregation of beta-2-microglobulin under physiopathological
conditions of dialysis-related amyloidosis. J Biol Chem 2006; 281:
16521–16529.
18. Inoue S, Kuroiwa M, Ohashi K et al. Ultrastructural organization of
hemodialysis-associated beta-2-microglobulin amyloid fibrils. Kidney Int
1997; 52: 1543–1549.
19. Ohishi H, Skinner M, Sato-Araki N et al. Glycosaminoglycans of
the hemodialysis-associated carpal synovial amyloid and of
amyloid-rich tissues and fibrils of heart, liver, and spleen. Clin Chem 1990;
36: 88–91.
20. Athanasou NA, Puddle B, Sallie B. Highly sulphated
glycosaminoglycans in articular cartilage and other tissues containing
beta-2-microglobulin dialysis amyloid deposits. Nephrol Dial Transplant
1995; 10: 1672–1678.
21. Morita H, Cai Z, Shinzato T et al. Glycosaminoglycans in dialysis-related
amyloidosis. Contrib Nephrol 1995; 112: 83–89.
22. Garbar C, Jadoul M, Noel H, van Ypersele de Strihou C.
Histological characteristics of sternoclavicular
beta-2-microglobulin amyloidosis and clues for its histogenesis. Kidney Int
1999; 55: 1983–1990.
23. McLaurin J, Franklin T, Zhang X et al. Interactions of Alzheimer
amyloid-beta peptides with glycosaminoglycans effects on fibril
nucleation and growth. Eur J Biochem 1999; 266: 1101–1110.
24. Cohlberg JA, Li J, Uversky VN, Fink AL. Heparin and other
glycosaminoglycans stimulate the formation of amyloid fibrils from
alpha-synuclein in vitro. Biochemistry 2002; 41: 1502–1511.
25. Suk JY, Zhang F, Balch WE et al. Heparin accelerates gelsolin
amyloidogenesis. Biochemistry 2006; 45: 2234–2242.
26. Yamaguchi I, Suda H, Tsuzuike N et al. Glycosaminoglycan and
proteoglycan inhibit the depolymerization of beta-2-microglobulin
amyloid fibrils in vitro. Kidney Int 2003; 64: 1080–1088.
27. Bellotti V, Stoppini M, Mangione P et al. Beta-2-microglobulin can be
refolded into a native state from ex vivo amyloid fibrils. Eur J Biochem
1998; 258: 61–67.
28. Esposito G, Michelutti R, Verdone G et al. Removal of the
N-terminal hexapeptide from human beta-2-microglobulin
facilitates protein aggregation and fibril formation. Protein Sci 2000; 9:
831–845.
29. Jones S, Smith DP, Radford SE. Role of the N- and C-terminal strands of
beta-2-microglobulin in amyloid formation at neutral pH. J Mol Biol 2003;
330: 935–941.
30. Myers SL, Thomson NH, Radford SE, Ashcroft AE. Investigating the
structural properties of amyloid-like fibrils formed in vitro from
beta-2-microglobulin using limited proteolysis and electrospray
ionisation mass spectrometry. Rapid Commun Mass Spectrom 2006; 20:
1628–1636.
180 Kidney International (2007) 72, 174–181
o r i g i n a l a r t i c l e AJ Borysik et al.: Glycosaminoglycans in dialysis-related amyloidosis
31. Monti M, Principe S, Giorgetti S et al. Topological investigation of amyloid
fibrils obtained from beta-2-microglobulin. Protein Sci 2002; 11:
2362–2369.
32. Yamaguchi K, Katou H, Hoshino M et al. Core and heterogeneity of
beta-2-microglobulin amyloid fibrils as revealed by H/D exchange. J Mol
Biol 2004; 338: 559–571.
33. Price FM, Levick JR, Mason RM. Changes in glycosaminoglycan
concentration and synovial permeability at raised intra-articular pressure
in rabbit knees. J Physiol 1996; 495: 821–833.
34. Price FM, Levick JR, Mason RM. Glycosaminoglycan concentration in
synovium and other tissues of rabbit knee in relation to synovial
hydraulic resistance. J Physiol 1996; 495: 803–820.
35. Worrall JG, Bayliss MT, Edwards JC. Morphological localization of
hyaluronan in normal and diseased synovium. J Rheumatol 1991; 18:
1466–1472.
36. Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in
the extracorporeal circuit: haemostasis and anticoagulation. Intensive
Care Med 1995; 21: 84–93.
37. O’Nuallain B, Wetzel R. Conformational Abs recognizing a generic
amyloid fibril epitope. Proc Natl Acad Sci USA 2002; 99: 1485–1490.
38. LeVine HI. Thioflavin T interaction with amyloid beta-sheet structures. Int
J Exp Clin Invest 1995; 2: 1–6.
39. Radford SE, Gosal WS, Platt GW. Towards an understanding of the
structural molecular mechanism of beta-2-microglobulin amyloid
formation in vitro. Biochim Biophys Acta 2005; 1753: 51–63.
40. Yamamoto S, Hasegawa K, Yamaguchi I et al. Kinetic analysis of the
polymerization and depolymerization of beta-2-microglobulin-related
amyloid fibrils in vitro. Biochim Biophys Acta 2005; 1753: 34–43.
41. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid beta-peptide (Abeta)
aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric
assay. Anal Biochem 1999; 266: 66–76.
42. Malemud CJ, Goldberg VM, Moskowitz RW et al. Biosynthesis of
proteoglycan in vitro by cartilage from human osteochondrophytic spurs.
Biochem J 1982; 206: 329–341.
43. Ohashi K, Kisilevsky R, Yanagishita M. Affinity binding of
glycosaminoglycans with beta-2-microglobulin. Nephron 2002; 90:
158–168.
44. Alexandrescu AT. Amyloid accomplices and enforcers. Protein Sci 2005;
14: 1–12.
45. Morgan CJ, Gelfand M, Atreya C et al. Kidney dialysis-associated
amyloidosis: a molecular role for copper in fiber formation. J Mol Biol
2001; 309: 339–345.
46. Giorgetti S, Rossi A, Mangione P et al. Beta-2-microglobulin isoforms
display an heterogeneous affinity for type I collagen. Protein Sci 2005;
14: 696–702.
47. Ward TT, Steigbigel RT. Acidosis of synovial fluid correlates with synovial
fluid leukocytosis. Am J Med 1978; 64: 933–936.
48. Sekijima Y, Wiseman RL, Matteson J et al. The biological and chemical
basis for tissue-selective amyloid disease. Cell 2005; 121: 73–85.
49. McParland VJ, Kalverda AP, Homans SW et al. Structural properties of an
amyloid precursor of beta-2-microglobulin. Nat Struct Biol 2002; 9:
326–331.
50. Platt GW, McParland VJ, Kalverda AP et al. Dynamics in the unfolded
state of beta-2-microglobulin studied by NMR. J Mol Biol 2005; 346:
279–294.
51. Katou H, Kanno T, Hoshino M et al. The role of disulfide bond in the
amyloidogenic state of beta-2-microglobulin studied by heteronuclear
NMR. Protein Sci 2002; 11: 2218–2229.
52. McCubbin WD, Kay CM, Narindrasorasak S et al. Circular-dichroism studies
on two murine serum amyloid A proteins. Biochem J 1988; 256: 775–783.
53. Castillo GM, Cummings JA, Yang W et al. Sulfate content and specific
glycosaminoglycan backbone of perlecan are critical for perlecan’s
enhancement of islet amyloid polypeptide (amylin) fibril formation.
Diabetes 1998; 47: 612–620.
54. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid by Congo red
spectral shift assay. Methods Enzymol 1999; 309: 285–305.
55. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from
amino acid sequence data. Anal Biochem 1989; 182: 319–326.
Kidney International (2007) 72, 174–181 181
AJ Borysik et al.: Glycosaminoglycans in dialysis-related amyloidosis o r i g i n a l a r t i c l e
